Seres Therapeutics Inc (NASDAQ: MCRB) on Monday, soared 5.42% from the previous trading day, before settling in for the closing price of $0.92. Within the past 52 weeks, MCRB’s price has moved between $0.54 and $2.05.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 386.36%. The company achieved an average annual earnings per share of 86.61%. With a float of $124.81 million, this company’s outstanding shares have now reached $170.20 million.
Let’s determine the extent of company efficiency that accounts for 233 employees. In terms of profitability, gross margin is -10887.5%, operating margin of -221404.69%, and the pretax margin is -258259.37%.
Seres Therapeutics Inc (MCRB) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Seres Therapeutics Inc is 26.90%, while institutional ownership is 23.58%. The most recent insider transaction that took place on Nov 18 ’24, was worth 475. In this transaction Chief Legal Officer and EVP of this company sold 878 shares at a rate of $0.54, taking the stock ownership to the 135,192 shares. Before that another transaction happened on Nov 18 ’24, when Company’s insider sold 977 for $0.54, making the entire transaction worth $528. This insider now owns 32,415 shares in total.
Seres Therapeutics Inc (MCRB) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 86.61% per share during the next fiscal year.
Seres Therapeutics Inc (NASDAQ: MCRB) Trading Performance Indicators
Seres Therapeutics Inc (MCRB) is currently performing well based on its current performance indicators. A quick ratio of 1.12 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2730.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.19, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.33 in one year’s time.
Technical Analysis of Seres Therapeutics Inc (MCRB)
Looking closely at Seres Therapeutics Inc (NASDAQ: MCRB), its last 5-days average volume was 2.4 million, which is a drop from its year-to-date volume of 4.23 million. As of the previous 9 days, the stock’s Stochastic %D was 67.61%. Additionally, its Average True Range was 0.09.
During the past 100 days, Seres Therapeutics Inc’s (MCRB) raw stochastic average was set at 54.46%, which indicates a significant decrease from 84.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.55% in the past 14 days, which was lower than the 103.09% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8019, while its 200-day Moving Average is $0.8801. However, in the short run, Seres Therapeutics Inc’s stock first resistance to watch stands at $1.0049. Second resistance stands at $1.0447. The third major resistance level sits at $1.0894. If the price goes on to break the first support level at $0.9204, it is likely to go to the next support level at $0.8757. Should the price break the second support level, the third support level stands at $0.8359.
Seres Therapeutics Inc (NASDAQ: MCRB) Key Stats
Market capitalization of the company is 163.81 million based on 170,738K outstanding shares. Right now, sales total 126,330 K and income totals -113,720 K. The company made 0 K in profit during its latest quarter, and 88,780 K in sales during its previous quarter.
